Related Experiment Video
Updated: Aug 16, 2026

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
Reprogramming HER2-Positive gastroesophageal cancer immune contexture with bispecific therapy: HERIZON-GEA-01
Raghav Sundar1, Samuel J Klempner2
1Department of Medicine, Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center New Haven, CT, USA.
None:
The HERIZON-GEA-01 trial in patients with advanced HER2-positive gastroesophageal adenocarcinoma demonstrated improved outcomes with the addition of the HER2xHER2-bispecific antibody zanidatamab to chemotherapy. The addition of tislelizumab, an anti-PD-1 antibody to chemotherapy and zanidatamab suggests additional survival improvements. HER2-targeting strategies leveraging spatially restricted target degradation and immune modulation are reframing HER2 approaches in HER2-positive gastroesophageal cancer.
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
